Participated · Equity · May 2024

Inheart develops an AI-driven digital twin of the heart as a medical device and software platform aimed at improving screening, early detection, and therapeutic support for cardiac disease. The company intends to expand commercially and deploy its solutions across the US, EU, Asia Pacific, and Middle East markets. It plans to use recent funding to develop new software solutions across the cardiac care continuum. Led by CEO Todor Jeliaskov, Inheart emphasizes personalized, predictive therapy to improve decision-making, efficiency of care, and safety of interventions. The announcement notes a USD11M funding round to support these initiatives. The company is based in Pessac, France. inHEART provides a cloud-based software solution that transforms preoperative medical images into a 3D digital twin of the patient’s heart to help plan procedures and assist instrument navigation. The technology is aimed at reducing procedure duration and failure rates during cardiac interventions for arrhythmias. The company plans to use new funding to accelerate commercial development in Europe, access the US market, and continue developing its AI and numerical simulations of cardiac electrical activity. Its technology has been used on more than 2,000 patients in 40 centers worldwide and has been included in the latest international expert recommendations. inHEART is a spin-off from IHU Liryc and Inria and was co-founded by Jean-Marc Peyrat, Prof. Pierre Jaïs, Maxime Sermesant and Hubert Cochet. The company is based in Pessac, France.

Participated · Series B · May 2022

Colorifix develops microbe-derived dyes by engineering bacteria and yeast to produce specific pigments that can be brewed and deposited directly onto textiles. Their process uses DNA databases to identify pigment genes, builds those genes into microbes, and scales them in vats to act as biological factories for dye production. A third-party life-cycle analysis paid for by Colorifix reports at least 49% less water use, 35% less electricity consumption and a 31% reduction in carbon emissions for natural fibers compared with conventional cotton dyeing; the company says savings are larger for synthetics like polyester and nylon. Colorifix has demonstrated limited commercial deployments—its dyes were used in a December 2021 Pangaia tracksuit run and in a Stella McCartney dress exhibited at the Victoria and Albert Museum in 2018—but has not yet reached mass production. With the $22.6M Series B led by H&M, Colorifix plans to significantly scale operations and triple its staff to about 120 people to push the technology into fashion supply chains. The company competes with other sustainable-dye startups such as Pili and Vienna Textile Lab and positions its approach as a lower-water, lower-energy alternative to conventional dyeing. Colorifix has developed a commercial biological dyeing process that engineers microbes to produce naturally occurring pigments and transfer color directly onto fabrics. The company converts agricultural by-products such as sugar molasses into colorants, enabling dyeing that uses around ten times less water and eliminates heavy metals, organic solvents and acids. Its technology has been applied commercially to polyamide-based jersey, polyester and cotton, with research underway to extend to other natural and synthetic fabrics. Colorifix reports independently certified quality test results and is positioning its solution as a scalable alternative to petrochemical-based dyeing. To support scale-up it is expanding a Norwich-based facility, building the team, and launching pilots with leading international fashion players. The company was founded in 2016 by Drs James Ajioka, Orr Yarkoni and David Nugent; Dr Orr Yarkoni serves as CEO.

Participated · Series C · Sep 2021

Homage operates a caregiving platform offering home visits from caregivers, nurses, therapists and doctors, plus telemedicine and services for chronic illnesses. Its platform uses a matching engine to help clients find providers best suited to their needs, with final matches made by Homage’s team. The company now has a regional network of more than 6,000 prescreened and trained care professionals. Homage says its business outside Singapore grew more than 600% year‑over‑year in 2021 and that it has more than tripled revenue over the past year. The new funding will be used to develop Homage’s technology, deepen integration with aged and disability care payer and provider infrastructure, and accelerate regional expansion through partnerships with hospitals and care providers. A Sheares Healthcare Group executive will join Homage’s board as part of the deal. Homage is a Singapore-based caregiving and telehealth company focused on patients who need long-term rehabilitation or care services, especially elderly people. Its core products include a caregiver-client matching platform and a home medical service that offers online consultations and house calls. The company currently operates in Singapore and Malaysia and is pursuing expansion into new Asian markets. Homage raised a Series B earlier this year to support its regional growth plans. Through a strategic investment and partnership with Infocom, Homage aims to launch services into Japan and help address the country’s caregiver shortage. Infocom’s technology footprint—used by more than 13,000 healthcare facilities in Japan—is intended to accelerate Homage’s regional expansion. Homage operates a tech-enabled caregiving marketplace that matches pre-screened, competency-assessed caregivers with families and care organisations. Its platform includes about 2,000 caregivers and supports elderly care plus rehabilitation services such as physiotherapy, speech and occupational therapy. Homage’s screening goes beyond interviews and background checks: it works with nurses to assess hands-on skills and encodes granular mobility and transfer technique data into a matching engine. The product also offers compliance tools and administrative features to help providers manage bookings, demand fluctuations and staff breaks to reduce burnout. Launched in 2016, Homage currently operates in Singapore and Malaysia and plans to expand into five more countries over the next two years. The company plans to use new funding to grow its caregiver base, provide training, and roll out new services including a medical delivery service. Homage is a Singapore-based startup that connects caregivers, organizations and care recipients through an on-demand platform. Founded in 2016 by Gillian Tee, Lily Phang and Tong Duong, the company offers six apps — two for caregivers, two for family members and two for partners such as NGOs and care agencies. It began focused on eldercare and has expanded into physiotherapy, speech and occupational therapy for post-stroke discharge. Homage emphasizes personalized one-on-one, often non-medical, support to help people remain mobile and live with dignity as they age. The company raised $4.15M in its latest funding and previously raised $1.2M a year earlier. Homage plans to use the new capital to push into other verticals and is exploring expansion into one other APAC market while continuing to focus on Singapore. Homage operates an asset-light platform that matches vetted, qualified caregivers with elderly clients for on-demand or regular scheduled in-home services. The company recruits and vets caregivers who must hold relevant qualifications and assigns the right caregiver based on seniors' needs or family requests. Homage aims to widen the pool of healthcare workers and to improve conditions compared with traditional employment agencies. The service went live in Singapore after launching in May 2016 and was founded by Gillian Tee with Lily Phang and Tong Duong. Financially, Homage has just closed a $1.2M seed round. The startup is initially focused on Singapore but is considering expansion to one other Southeast Asian country within the next two years.